INOVIO presents at Jefferies 2021 Virtual Healthcare Conference | 2021-05-25 | Press releases


PLYMOUTH MEETING, Pa. , May 25, 2021 / PRNewswire / – INOVIO (NASDAQ: INO), a biotechnology company focused on bringing precisely engineered DNA drugs to the treatment and protection of people from infectious diseases, cancer, and HPV-related diseases, announced today, that Dr. Joseph Kim The President and CEO is expected to attend a fireside chat and 1×1 investor meeting at the Jefferies 2021 Virtual Healthcare Conference on Tuesday 1st June 2021 at the 2 p.m. EDT . A webcast of the event is available at the following link:

Via INOVIO’s DNA Medicines Platform

INOVIO currently has 15 DNA medicine clinical programs focused on HPV-related diseases, cancer and infectious diseases, including coronaviruses related to MERS and COVID-19 diseases, funded through grants from the Coalition for Epidemic Preparedness Innovations (CEPI) and the US Department of Defense. DNA drugs are made up of optimized DNA plasmids, small circles of double-stranded DNA that are synthesized or reorganized using computer sequencing technology and designed to produce a specific immune response in the body.

INOVIO’s DNA drugs deliver optimized plasmids directly into cells intramuscularly or intradermally with the handheld smart device CELLECTRA developed by INOVIO & circledR; . THE CELLECTRA & circledR; The device uses a short electrical pulse to reversibly open small pores in the cell to allow the plasmids to enter, overcoming a significant limitation of other DNA and other nucleic acid approaches such as mRNA. Once inside the cell, the DNA plasmids allow the cell to produce the target antigen. The antigen is naturally processed in the cell and triggers the desired T-cell and antibody-mediated immune responses. Administration with the CELLECTRA & circledR; The device ensures that the DNA drug is efficiently delivered directly into the body’s cells where it can go to work to trigger an immune response. INOVIO’s DNA drugs do not interfere or alter an individual’s own DNA in any way. The advantages of INOVIO’s DNA medical platform are how quickly DNA drugs can be developed and manufactured. the stability of products that do not need to be frozen during storage and transport; and the robust immune response, safety profile, and tolerability observed in clinical trials.

With more than 3,000 patients receiving INOVIO investigational DNA drugs in more than 7,000 uses across a range of clinical trials, INOVIO has a long history of rapidly generating DNA drug candidates that have the potential to address urgent global health needs .


INOVIO is a biotechnology company focused on rapidly bringing to market precisely engineered DNA drugs to treat and protect people from infectious diseases, cancer, and HPV-related diseases. INOVIO is the first and only company to have clinically proven that a DNA drug can be delivered directly into the body’s cells via a proprietary intelligent device to generate a robust and tolerable immune response. In particular, INOVIO’s lead candidate VGX-3100 is the first DNA drug to reach efficacy endpoints in a Phase 3 clinical trial, REVEAL 1, for the treatment of precancerous cervical dysplasia caused by HPV-16 and / or HPV-18. VGX-3100 also demonstrated positive Phase 2 efficacy results in separate studies evaluating the treatment of precancerous vulvar dysplasia and anal dysplasia. Programs against HPV-related cancers and a rare HPV-related disease, recurrent respiratory papillomatosis (RRP), are also being developed; non-HPV-related cancers glioblastoma multiforme (GBM) and prostate cancer; as well as externally funded development programs for DNA vaccines against infectious diseases in Zika, Lassa fever, Ebola, HIV and coronaviruses related to MERS and COVID-19 diseases. Partners and collaborators include Advaccine, ApolloBio Corporation, AstraZeneca, Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovation (CEPI), Agency for Advanced Defense Research Projects (DARPA) / Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) / Department of Defense (DoD), HIV Vaccine Studies Network, International Vaccine Institute (IVI), Kaneka Eurogentec, CBRN Medical Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and infectious diseases, Ology Bioservices, Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania , Walter Reed Army Institute of Research and The Wistar Institute. INOVIO is also a proud recipient of the “Women on Boards” W “2020” award, which recognizes companies with more than 20% women on their board of directors. More information is available at


Media: Jeff Richardson 267-440-4211, [email protected]

Investors: Ben Matone 484-362-0076, [email protected]

This press release contains certain forward-looking statements about our business, including our plans to develop and commercialize DNA drugs, our expectations of our research and development programs, including the planned initiation and conduct of preclinical and clinical trials, and the availability and timing of Data from these studies and trials and our ability to successfully manufacture and produce large quantities of our product candidates once they receive regulatory approval. Actual events or results could differ from expectations set forth here due to a number of factors, including uncertainties associated with preclinical studies, clinical trials, product development programs, and commercialization activities and results, mass production of our product candidates, availability of funding to support ongoing research and studies to prove the safety and effectiveness of electroporation technology as a delivery mechanism or to develop viable DNA drugs, our ability to support our pipeline of DNA medical devices, the ability of our people to reach development and commercial milestones for products we license and achieve product sales that enable us to anticipate future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies, or B. Obtaining action for the conditions we seek or employees, including alternatives This may be more effective or less expensive than any therapy or treatment that we and our employees wish to develop. Issues related to product liability, issues related to patents, and whether they, or licenses to them, provide us with meaningful protection from others using the technologies covered. whether such property rights are enforceable or defensible, or violate or allegedly violate the rights of others, or stand up against claims for invalidity; and whether we can fund or use other significant resources necessary to pursue, protect or defend them, corporate spending, estimates of our technology by potential companies or other partners or employees, capital market conditions, the impact of government health proposals, and other factors detailed in our Annual Report on Form 10-K for the past year December 31, 2020 , our quarterly report on Form 10-Q for the quarter ended March 31, 2021 and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any candidate product in our pipeline will be successfully developed, manufactured, or commercialized, that the final results of clinical studies will support the regulatory approvals required to market a product, or that the forward-looking information contained herein will be proven to be accurate. Forward-looking statements speak only as of the date of this publication and we assume no obligation to update or revise these statements unless required by law.

View original content:

SOURCE INOVIO Pharmaceuticals, Inc.

Source link


Comments are closed.